A study published by the International Journal of Molecular Sciences finds that cannabidiol (CBD) may selectively damage cancer cells while having a more limited effect on non-cancerous cells. The research was conducted by scientists from Universidad Autónoma de Nuevo León in Mexico and focused on CBD’s cytotoxic effects across several human cell lines.
Researchers tested CBD on three cancer cell lines—HeLa (cervical cancer), MDA-MB-231 (triple-negative breast cancer), and CaCo-2 (colorectal cancer)—alongside two non-cancerous control cell lines, HaCaT (human keratinocytes) and HUVEC (human endothelial cells). Cells were exposed to CBD concentrations of 5, 10, and 20 micromolar over periods ranging from 24 to 96 hours.
Using MTT assays to measure cell viability, the team found that CBD reduced cancer cell survival in a dose- and time-dependent manner. The median lethal concentration at 24 hours was calculated at 9.4 micromolar for HeLa cells, 10.3 micromolar for MDA-MB-231 cells, and 4.3 micromolar for CaCo-2 cells, indicating particularly high sensitivity in colorectal cancer cells.
Additional analysis using DAPI nuclear staining and flow cytometry showed morphological changes consistent with cell stress, apoptosis, and necrosis in cancer cells following CBD exposure. These changes became more pronounced with longer exposure times. Importantly, the non-cancerous control cells were less affected under the same conditions.
The authors conclude that CBD demonstrates selective cytotoxicity toward malignant cells compared to non-malignant cells, supporting further investigation into its potential role as an adjunctive therapy in cancer treatment. They emphasize that these findings are based on in vitro data and that additional research would be required before any clinical applications could be considered.
Sponsored
